GSK melanoma move
November 16, 2010
GLAXOSMITHKLINE this
morning announced Phase III trials
of its investigational BRAF inhibitor
for treatment of melanoma.
The trials will take place at
several Australian sites before the
end of the year, and will compare
the GSK2118436 candidate with
the efficacy, safety and tolerability
of dacarbazine (DTIC).
The study, which is currently
undergoing ethics approval, will
enrol subjects with BRAF mutant
advanced (Stage III) or metastatic
(Stage IV) melanoma.
About 50% of human melanomas
involve a mutation of the gene for a
protein called BRAF, with the
investigative agent binding to the
activated form of the BRAF protein
in the melanoma cell which causes
it to stop proliferating.
“Clinical trials that focus on
potential new treatments are
crucial, given that melanoma
claims the lives of 1250 Australians
each year,” said Melanoma Patients
Australia ceo Lisa McFadyen.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Nov 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Nov 10
